MedTrace Logo

Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease

NCT00911794 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2009-06-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

Conditions

Interventions

OTHER

Disclosure Writing (Written Disclosure Therapy)

Patients write about a stressful life experience

OTHER

Neutral (Sham) Writing

Patients write about neutral subjects

Sponsors & Collaborators

  • Stony Wold-Herbert Fund, Inc.

    collaborator OTHER

  • Winthrop University Hospital

    lead OTHER

Principal Investigators

  • Adam Hurewitz, M.D. · Winthrop University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-01-31
Completion
2009-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911794 on ClinicalTrials.gov